How to Have Better Sex After Menopause

Why Sex Changes After Menopause (and Why It Doesn't Have to Stay That Way)

The shift in sexual experience at menopause is driven by biology, not destiny. When ovarian estrogen production drops, vaginal tissue loses collagen and moisture, the clitoris may become less sensitive, and orgasm can take longer or feel less intense. These are real physiological changes. They are also, in most cases, treatable.

Up to 84% of postmenopausal women report at least one sexual problem, yet fewer than 25% discuss it with a clinician. That gap between prevalence and treatment is the single biggest obstacle to better sex after menopause.

What Estrogen Loss Does to Your Body

Estrogen keeps vaginal walls thick, elastic, and well-lubricated. After menopause, those walls thin, surface pH rises from roughly 4.5 to 6.0 or higher, and blood flow to the genitals decreases. The result is genitourinary syndrome of menopause (GSM), a cluster of symptoms including dryness, burning, pain with penetration (dyspareunia), and reduced arousal. Unlike hot flashes, GSM does not improve on its own over time. It typically worsens without treatment.

The Libido Layer

Physical discomfort is only part of the picture. Testosterone, which drives sexual desire in women as in men, also declines gradually through the menopausal transition. Lower testosterone combined with the psychological weight of pain during sex, body-image shifts, and partner dynamics creates a cycle: sex hurts, so desire falls, so arousal is harder to achieve, so sex hurts more.

Breaking that cycle requires addressing both layers at once.

Genitourinary Syndrome of Menopause: Your First Clinical Priority

GSM is the most common physical reason sex becomes painful or unsatisfying after menopause. Treating it is the foundation of everything else.

Local (Vaginal) Estrogen

Low-dose vaginal estrogen delivers estrogen directly to vaginal and vulvar tissue with minimal systemic absorption. ACOG's 2024 clinical practice guideline on GSM lists local vaginal estrogen as a first-line treatment. Available forms include:

• Cream (conjugated estrogens 0.5 g or estradiol 2 g applied 2-3 times per week after a loading phase)
• Vaginal tablet or suppository (estradiol 10 mcg nightly for 2 weeks, then twice weekly)
• Soft-gel capsule (estradiol 4 mcg or 10 mcg, inserted vaginally twice weekly)
• Ring (estradiol 7.5 mcg/day, replaced every 90 days)

Systemic estrogen levels with these products remain within normal postmenopausal range. Women with a history of hormone-receptor-positive breast cancer should discuss local estrogen with their oncologist; current ACOG guidance notes that for women experiencing significant GSM symptoms who have exhausted non-hormonal options, the decision should be individualized.

Ospemifene

Ospemifene 60 mg taken orally once daily is an FDA-approved selective estrogen receptor modulator (SERM) that acts like estrogen on vaginal tissue without requiring insertion. In the key SMART trials, it reduced dyspareunia scores significantly compared to placebo and improved vaginal maturation index. It is a reasonable option if you prefer not to use anything vaginally and do not have a history of breast cancer or active thromboembolic disease. Ospemifene carries a potential increased risk of uterine stimulation, so women with a uterus should be monitored, though it is not currently prescribed with a progestogen.

Intravaginal Prasterone (DHEA)

Prasterone (Intrarosa) 6.5 mg nightly is a vaginally inserted DHEA suppository that converts locally to estrogen and testosterone within vaginal cells. The AMETHYST trial showed significant improvement in dyspareunia and vaginal dryness over 52 weeks. Because conversion is local, systemic hormone levels remain in the postmenopausal range. It is an option for women who want local treatment without prescribing estrogen by name.

Lubricants and Moisturizers: The Underrated Essentials

No prescription is required for two of the most effective tools in this space.

Vaginal moisturizers (polycarbophil-based products like Replens, or hyaluronic acid-based gels) are used regularly, two to three times per week, to restore baseline moisture and lower pH. They are not just for sex. In a head-to-head trial published in Menopause, hyaluronic acid gel improved vaginal dryness scores similarly to low-dose vaginal estrogen over 12 weeks in women with mild to moderate GSM, though local estrogen remains more effective for moderate to severe symptoms.

Lubricants are used at the moment of sexual activity. Silicone-based lubricants last longer and are not absorbed; water-based lubricants are safe with all toys and condoms but may need reapplying. Avoid products containing glycerin (fermentation risk), parabens, or fragrances. Oil-based products degrade latex condoms and increase infection risk.

A practical rule: use a moisturizer regularly AND a lubricant every time. These are not alternatives to each other.

Addressing Low Libido After Menopause

Low sexual desire is distinct from GSM but often coexists with it. Hypoactive sexual desire disorder (HSDD) is the most common female sexual dysfunction diagnosis, affecting approximately 10% of premenopausal women and a higher proportion of postmenopausal women, though exact rates vary by definition and population.

Testosterone for Women

Off-label testosterone is the most evidence-supported treatment for low libido in postmenopausal women, though no testosterone product is currently FDA-approved specifically for women in the United States.

A 2019 systematic review and meta-analysis in The Lancet Diabetes & Endocrinology covering 36 randomized trials found that testosterone therapy significantly improved sexual function scores, desire, arousal, and orgasm frequency compared to placebo or comparator in postmenopausal women. The global consensus on women's testosterone, endorsed by multiple endocrine and sexual medicine societies, recommends targeting a serum total testosterone level in the physiological premenopausal range (roughly 15-70 ng/dL depending on assay) using transdermal preparations at one-tenth to one-twentieth the male dose.

Typical off-label approaches include compounded testosterone cream or gel at 0.5-2 mg per day applied to the inner arm or thigh, or the use of a small portion of a male-formulated testosterone gel. Because compounded products vary in concentration, consistent sourcing matters.

Monitoring every 3-6 months for signs of androgen excess (acne, hair changes, voice changes) is standard practice.

Flibanserin (Addyi)

Flibanserin 100 mg taken orally at bedtime is FDA-approved for HSDD in premenopausal women, with off-label use in postmenopausal women supported by the same mechanism: central serotonin and dopamine modulation to increase sexual motivation. It requires alcohol avoidance and should not be used with moderate or strong CYP3A4 inhibitors. Side effects include dizziness, somnolence, and nausea, which is why the bedtime dosing matters.

Bremelanotide (Vyleesi)

Bremelanotide 1.75 mg is a subcutaneous self-injection taken 45 minutes before anticipated sexual activity, approved for HSDD in premenopausal women and used off-label postmenopausally. It activates melanocortin receptors. The main side effects are nausea (reported in roughly 40% of users) and transient blood pressure elevation, so it is not appropriate for women with uncontrolled hypertension or cardiovascular disease.

Pelvic Floor Health: The Often-Skipped Piece

Menopause-related changes in connective tissue affect the pelvic floor. Muscles that were once supple may become tight (creating pain with penetration) or weak (reducing sensation and orgasm strength). Both directions of dysfunction are real and both respond to targeted treatment.

Pelvic floor physical therapy (PFPT) with a trained women's-health physiotherapist is the first intervention to try for dyspareunia not fully explained by GSM alone. Therapy includes internal and external manual techniques, biofeedback, and graduated dilator use. In women with high-tone pelvic floor dysfunction, strengthening exercises alone make symptoms worse. An assessment first, not generic Kegel instructions.

Vaginal dilators used consistently, with lubricant, help maintain or restore vaginal caliber, particularly for women who are not sexually active with a partner and want to preserve tissue elasticity.

Clitoral Stimulation, Orgasm, and Anatomy After Menopause

Orgasm takes longer after menopause. That is not failure; it is physiology. Reduced blood flow means the clitoris engorges more slowly and the plateau phase extends. The practical response: more time, not a different partner or a diagnosis.

A useful clinical framework for postmenopausal orgasm is the 3-T model: Time, Touch type, and Tools.

• Time: Build in more time for arousal before any penetration. Twenty to thirty minutes of non-genital and genital touch before intercourse is not unusual or excessive for postmenopausal women.
• Touch type: The glans clitoris may be more sensitive to pain than pleasure after estrogen loss. Indirect stimulation through the clitoral hood or inner labia may be more comfortable than direct contact. Local estrogen often improves this within 8-12 weeks.
• Tools: Vibrators designed for clitoral stimulation have the strongest evidence base. The EROS clitoral therapy device (a small vacuum device cleared by the FDA) increases clitoral blood flow and has published data in Obstetrics and Gynecology showing improved arousal and orgasm in postmenopausal women.

Sex With or Without a Partner: Both Are Valid Starting Points

Sexual well-being after menopause is not contingent on having a partner. Solo sexual activity maintains genital blood flow, preserves vaginal tissue elasticity, and contributes to overall pelvic floor health. Women who remain sexually active (with or without a partner) after menopause show better preserved vaginal tissue on clinical assessment than those who are not.

For women with partners, communication about changed anatomy, different timing needs, and treatment plans is part of the clinical picture. Some clinicians recommend a partner visit, not because the partner is the patient, but because shared understanding of what is physiologically happening reduces the psychological weight that often compounds physical symptoms.

New partners after menopause introduce an additional consideration: STI risk. Postmenopausal women have lower condom use rates than younger women, and thinned vaginal tissue may increase susceptibility to some infections. CDC data show rising STI rates in adults over 55. Use barrier methods with new partners regardless of contraception status.

Contraception, Pregnancy, and Lactation Considerations

Contraception in Perimenopause

You are not postmenopausal until 12 consecutive months without a period. During perimenopause, ovulation is erratic but possible. Pregnancy in your late 40s carries substantially higher risks, including chromosomal abnormalities, gestational hypertension, and placental complications. ACOG recommends continuing contraception until confirmed menopause (FSH above 30 IU/L on two measurements at least 6 weeks apart, combined with 12 months of amenorrhea).

Low-dose combined hormonal contraceptives remain an option for healthy non-smoking perimenopausal women and carry the added benefit of cycle regulation and symptom management. Progestogen-only pills, the levonorgestrel IUD, and the copper IUD are all appropriate for this stage.

Pregnancy Safety of GSM Treatments

All medications used specifically for postmenopausal GSM (local estrogen, ospemifene, prasterone) are contraindicated in pregnancy. Ospemifene in particular carries an FDA pregnancy category X equivalent under the new labeling system, meaning known fetal risk outweighs any benefit. The FDA label for ospemifene states it should not be used during pregnancy, and women of reproductive potential should use effective contraception.

Flibanserin is also contraindicated in pregnancy. The prescribing information requires enrollment in a Risk Evaluation and Mitigation Strategy (REMS) program partly because of reproductive risk, and women who could become pregnant must use contraception.

Bremelanotide has no adequate human pregnancy data; animal studies showed embryo-fetal toxicity at high doses. Contraception is required for women of reproductive potential.

Lactation

GSM treatments are irrelevant in the lactation context (postmenopausal by definition), but for completeness: vaginal estrogen products at standard doses have minimal systemic absorption and are generally considered compatible with lactation when used for postpartum GSM, though this is a different clinical scenario. The Menopause Society and ACOG do not address lactation in postmenopausal GSM guidelines because the populations do not overlap.

Who This Is Right For, and Who Should Be Cautious

Women Who Are Good Candidates for Local Estrogen

• Postmenopausal women with GSM symptoms (dryness, dyspareunia, burning)
• Women who cannot or prefer not to use systemic hormone therapy
• Women with a breast cancer history in discussion with their oncologist
• Women on aromatase inhibitors (discuss with oncologist; some data support cautious use of very low-dose local estrogen when lubricants and ospemifene have failed)

Women Who Should Avoid Estrogen-Containing GSM Treatments

• Active or recent hormone-receptor-positive breast cancer (without oncologist clearance)
• Unexplained vaginal bleeding
• Active thromboembolic disease (for systemic estrogen specifically)

Women for Whom Testosterone May Help Most

• Postmenopausal women with documented low desire that is distressing and not explained by relationship factors or GSM alone
• Women who have tried and optimized GSM treatment but still have low libido
• Women with surgical menopause (bilateral oophorectomy), who lose testosterone abruptly and often report a steeper drop in desire

Women Who Need Pelvic Floor Therapy First

• Women with pain localized to the vaginal entrance (introitus) that is sharp or burning on attempted penetration
• Women with a history of pelvic surgery, prolapse, or significant childbirth trauma
• Women whose pain is not relieved after 8-12 weeks of local estrogen

Putting It Together: A Practical Sequence

The evidence supports a stepwise approach rather than trying everything at once.

Step 1 (weeks 1-4): Start a vaginal moisturizer two to three times per week. Add a quality lubricant every time you have sex. Give your body 4-8 weeks before judging efficacy.

Step 2 (week 4 onward, with clinician): If moisturizers alone are insufficient, add local vaginal estrogen or prasterone. Expect 8-12 weeks for full tissue restoration. Most women notice improvement in dryness and some comfort within 4 weeks.

Step 3 (concurrent): If low desire is a primary complaint, discuss testosterone (off-label, transdermal) with a clinician experienced in women's hormones. Baseline levels and a 3-6 month monitoring plan are standard.

Step 4 (if pain persists): Refer to a pelvic floor physiotherapist before adding further medications. Pain with penetration that does not respond to local estrogen and lubricants is often a pelvic floor issue, not a hormone deficiency.

Step 5 (if desire remains low after GSM is treated): Consider flibanserin or bremelanotide, with an honest conversation about their modest effect sizes and side-effect profiles.

The Menopause Society's 2022 position statement on sexual health underscores that combined treatment of both physical and psychological dimensions is more effective than treating either alone. Their statement notes: "Treatment of sexual dysfunction in menopause requires individualized, multimodal management addressing physiologic, psychological, and relational factors."

A Note on the Evidence Gap

Women have been systematically underrepresented in sexual-function research for decades. Most GSM trials enrolled women within 5-10 years of menopause onset, predominantly white, and with partners. Data for women over 70, women of color, women with disabilities, and women in same-sex relationships are thin. The effect of race and ethnicity on GSM severity and treatment response is largely unknown.

As our reviewer, Dr. Elena Vasquez, notes: "The clinical reality is that I see women in their 60s and 70s who have spent years assuming painful sex was just what menopause meant. The evidence base we have is imperfect, but it is good enough to act on. Waiting for a perfect trial is not a patient-centered approach."

This is an honest limitation, not a reason to avoid treatment.